# ISCT Conference Program

## Sunday April 21, 2013

- **4:00pm – 7:00pm** ***REGISTRATION***  
  Auckland Promenade

## Monday April 22, 2013

- **7:00am – 7:00pm** ***REGISTRATION***  
  Auckland Promenade
- **8:00am – 5:30pm** Global Regulatory Perspectives Workshop  
  New Zealand 1, 2
- **9:00am – 4:30pm** Flow Cytometry Workshop  
  Offsite at the Maurice Wilkins Centre
- **8:00am – 5:00pm** FACT Training Workshop  
  Marlborough 2
- **5:00pm – 7:00pm** Corporate Symposium **Milenyi Biotec** (Refer to Corporate Guide for Details)  
  New Zealand 3, 4
- **7:00pm – 7:30pm** Welcome Address  
  New Zealand 1, 2
- **7:30pm – 9:30pm** Welcome Reception  
  Auckland Room

## Tuesday April 23, 2013

- **7:00am – 4:00pm** ***REGISTRATION***  
  Auckland Promenade
- **7:30am – 8:30am** STRATEGIES FOR COMMERCIALIZATION TRACK 1  
  Cell Characterization for Commercialization of Cell Therapies  
  **CO–CHAIRS:** **STEVE OH** (SG) AND **GUY MOENECLAEMY** (AU)
  - **SPEAKERS:**
    - **Mark Bonyhadi** (US) – Leveraging new approaches for cell therapy product characterization: Identity, Purity and Safety Testing
    - **Jyoti Arora** (AU) – In vivo characterisation of cellular therapy products for commercialisation using medical imaging
    - **Ming Hao Zheng** (AU) – Process characterization of autologous somatic cellular product: the 10 year R&D experiences
- **7:30am – 8:30am** QUALITY AND OPERATIONS TRACK 1  
  Immunotherapy Technical Topics  
  **CHAIR:** **RUSSELL CRUZ** (US)
  - **SPEAKERS:**
    - **Kenneth Micklethwaite** (AU) – Muscle CAR Maintenance – Quality systems and CAR T–cells
    - **Janice Fogarty** (AU) – Mesenchymal Stromal Cell Therapy
- **7:30am – 8:30am** STRATEGIES FOR COMMERCIALIZATION TRACK 2  
  By the way, Who’s Paying for All of This?  
  **CHAIR:** **DAWN DRISCOLL** (AU)
  - **SPEAKERS:**
    - **Richard Maziarz** (US) – Perspectives on cell therapy reimbursement from the front lines of medicine
    - **Jim Butler** (AU) – The HTA imperative: Key issues in securing reimbursement

Coffee and tea will be available prior to the start of the first morning sessions.
Tuesday April 23, 2013 continued

8:45am – 9:00am OPENING REMARKS by Kurt Gunter

9:00am – 10:30am PLENARY SESSION 1 – PRESIDENTIAL PLENARY PLURIPOTENT STEM CELLS
CHAIR: KURT GUNTER (US)
SPEAKERS:
David Ma (AU) – Reprogramming somatic cells to the pluripotent state for use in cellular therapy
Mahendra Rao (US) – Manufacturing stem cell derivatives for screening and therapy
Alan Davidson (NZ) – Modelling cystinosis with induced pluripotent stem cells

10:30am – 11:00am COFFEE BREAK WITH EXHIBITS

11:00am – 12:15pm ORAL ABSTRACT PRESENTATIONS 1
Mesenchymal Stem Cells
CHAIR: LUC SENSEBÉ (FR)
PRESENTERS:
Allan Dietz (US) – Data in support of the clinical use of adipose derived MSC: growth, storage, function and safety
Caroline Gargett (AU) – A tissue engineering construct comprising human endometrial mesenchymal stromal cells and polyamide/gelatin mesh evaluated in a preclinical animal model of pelvic organ prolapse repair
Sze Chin (MY) – Intra articular injection of autologous bone marrow-derived mesenchymal stromal cells in patients with moderate to severe osteoarthritis
Steve Oh (SG) – Extracellular matrix free microcarrier cultures of human pluripotent stem cells induced by inhibition of rock-myosin II signaling

11:00am – 12:15pm ORAL ABSTRACT PRESENTATIONS 2
Hematopoietic Stem Cells
CHAIR: EJ SHPALL (US)
PRESENTERS:
Marc Turner (UK) – Progress towards the cGMP production of pluripotent stem cell derived red blood cells
Alla Dolnikov (AU) – GSK-3ß inhibition promotes T cell reconstitution and preserves naïve T cell phenotype in mice transplanted with human haematopoietic stem cells.
Ian McNiece (US) – Bone marrow versus PBPC for allogeneic stem cell transplant: defining the optimal graft
Russell Cruz (US) – Infusion of CD19-directed/multivirus specific-cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation for B cell malignancies
Amit Khot (AU) – Low dose lenalidomide induction followed by autologous transplantation in untreated patients with myeloma is associated with adequate collection of haematopoietic and dendritic cell precursors and high response rates

11:00am – 12:15pm ORAL ABSTRACT PRESENTATIONS 3
Quality and Operations
CO–CHAIRS: DOMINIC WALL (AU) AND THOMAS LEEMHUIS (US)
PRESENTERS:
Robert Nordon (AU) – Mapping and modelling ex vivo cell culture processes directly from cell tracking data
Patricia Distler (US) – Revisions to ISBT 128 nomenclature for cellular therapy
Maniele Viganò (IT) – Analytical procedures validation for good manufacturing practice (GMP) production of mesenchymal stem cells from different sources
Chih Wei (UK) – Regulatory blind spots in cellular therapy translation experience from Australia
Marc Turner (UK) – Establishment of a bank of blood donor derived Epstein Barr virus specific T cell lines for treatment of post-transplant lymphoproliferative disease.
**Tuesday April 23, 2013 continued**

### STRATEGIES FOR COMMERCIALIZATION TRACK 3

**Risk in Cell Therapy Commercialization**  
**CHAIR:** CHRISTOPHER BRAVERY (UK)  
**SPEAKERS:**  
- Ronnda Bartel (US) – Commercial strategies for ixmyelocel–T, a novel autologous therapy for severe, chronic cardiovascular disease  
- Miles Prince (AU) – Assessing Risk in Cell Therapy Clinical Trials  
- Lucy Foley (UK) – Considerations for the Widespread Adoption of Limbal Stem Cell Transplantation

### LUNCH WITH EXHIBITS

**Auckland Room**

**12:30pm – 1:30pm**  
Corporate Tutorial  
**GE Healthcare**  
(Refer to Corporate Guide for Details)  
New Zealand 3, 4  
Corporate Tutorial  
**BioLife Solutions**  
(Refer to Corporate Guide for Details)  
New Zealand 1, 2  
Corporate Tutorial  
**Corning Life Sciences**  
(Refer to Corporate Guide for Details)  
Epsom 1, 2, 3

### PLENARY SESSION 2 – NOVEL APPROACHES USING MSCs

**New Zealand 1, 2**

**1:45pm – 3:15pm**  
**CHAIR:** EJ SHPALL (US)  
**SPEAKERS:**  
- EJ Shpall (US) – Mesenchymal stem cells to enhance cord blood engraftment  
- Edwin Horwitz (US) – MSCs for Bone Regeneration: it’s not what you think!  
- Paul Simmons (AU) – Mesenchymal Precursor Cells (MPC): A platform technology for multiple therapeutic applications

### QUALITY AND OPERATIONS TRACK 2

**Marlborough 1, 2, 3**

**1:45pm – 3:15pm**  
**CHAIR:** SHIRLEY BARTIDO (US)  
**SPEAKERS:**  
- Julie Allickson (US) – Considerations for Tissue Engineering & Regenerative Medicine Product Development Prior to Clinical Trials  
- Allan Dietz (US) – Organizing the IND: Templates and Processes to Speed IND Preparation  
- Xiuyan Wang (US) – Large-Scale Clinical–Grade Retroviral Vector Production In iCELLis Nano Bioreactor

### COFFEE BREAK WITH EXHIBITS

**Auckland Room**

**3:30pm – 5:00pm**  
**WORKSHOP 1**  
**Tumor Vaccines and Beyond**  
**CHAIR:** JOHN BARRETT (US)  
**SPEAKERS:**  
- Jonathan Serody (US) – Using Autologous Stem Cell Transplantation as a Platform for Building Tumor Vaccination  
- J H Frederik Falkenburg (NL) – Benefit and Risk of targeting HLA Class–II in the treatment of hematological malignancies  
- John Barrett (US) – Prevention of leukemic relapse after allogeneic stem cell transplantation with leukemia-specific T cells

**WORKSHOP 2**  
**Hot Topics in Haplo and Cord Transplant**  
**CHAIR:** CATHERINE BOLLARD (US)  
**SPEAKERS:**  
- Xiao-Jun Huang (CN) – Improving outcomes after Haploidentical SCT  
- Satoshi Takahashi (JP) – Strategies to improve the cord blood engraftment— a Japanese perspective  
- Patrick Hanley (US) – Improving immune reconstitution after cord blood and haploidentical SCT
3:30pm – 5:00pm

**STRATEGIES FOR COMMERCIALIZATION TRACK 4**

Unique Approaches in Cell Therapy Commercialization

**CHAIR:** DAVID RITCHIE (AU)

**SPEAKERS:**
- Paul Tan (NZ) – Taking the pig to market: LCT’s regulatory and commercial journey so far
- Brian Salmons (SG) – Less can be more: reducing dose and increasing efficacy using encapsulated cells
- Robert Short (AU) – Making Cell Therapy Affordable and Accessible: An Introduction to the new Co–operative Research Centre for Cell Therapy Manufacturing (Australia)

3:30pm – 5:00pm

**QUALITY AND OPERATIONS TRACK 3**

Validation/Verification/Qualification

**CHAIR:** CAROLYN KEEVER–TAYLOR (US)

**SPEAKERS:**
- Carolyn Keever–Taylor (US) – Qualification, Validation, Verification. What, When, How?
- Martin Hildebrandt (DE) – Qualification of a facility – hints and pitfalls
- Lizette Caballero (US) – ISBT Labeling of Cellular Therapy Products: From Planning to Collection to Transplant

5:00pm – 6:00pm

**MASTER CLASS 1**

ISCT–ISBT Joint Session: Biobanking and Biomarkers

**CHAIR:** PETER FLANNAGAN (NZ)

**SPEAKERS:**
- Roy Jones (US) – Informatics to Optimize Stem Cell Transplantation (SCT) and Cell Processing Lab Function
- Michael Kalos (US) – Development and implementation of correlative studies for cell therapy trials
- Mickey Koh (SG/UK) – Biobanking: A treasure trove for cure

5:00pm – 6:30pm Poster Session 1

5:00pm – 6:30pm

**MASTER CLASS 2**

Access to Unproven Cell Therapies

**CHAIR:** KURT GUNTER (US)

**SPEAKERS:**
- Alok Srivastava (IN) – Stem Cells: From Clinical Trials to Standard of Care– How do we decide?
- Doug Sipp (JP) – Regulatory responses to the premature commercialization of ‘stem cell’ interventions
- Steve Wilton (AU) – Hypothesis driven research vs snake oil; validated outcomes, hope and hype for neuromuscular diseases

**Wednesday April 24, 2013**

**REGISTRATION**

**7:00am – 4:00pm**

**Auckland Promenade**

**7:30am – 8:30am**

**TECHNICAL SESSION 1**

Hands on Dendritic Cell Technology

**CO–CHAIRS:** DEREK HART (AU) AND JAMES YOUNG (US)

**SPEAKERS:**
- Derek Hart (AU) – Dendritic cell subsets in 2013
- Rod Dunbar (NZ) – Dendritic cell antigen delivery – methodology in 2013
- James Young (US) – Langerhans cells versus monocyte derived dendritic cells: challenges and opportunities

**7:30am – 8:30am**

**STRATEGIES FOR COMMERCIALIZATION TRACK 5**

Upstream Sourcing for Commercial Products

**CHAIR:** KNUT NISS (US)

**SPEAKERS:**
- Dominic Clarke (US) – Single–Use Technologies in Cell Therapy: Strategies for Implementation
- Ohad Karnielni (IL) – Challenges and possible solutions to overcome the gap in critical supply chain issues of new and evolving cutting edge technologies of cell therapy
- Ian Fitzpatrick (AU) – Upstream Processing of Cellular Therapies: Challenges and Solutions

---

Coffee and tea will be available prior to the start of the first morning sessions.
### QUALITY AND OPERATIONS TRACK 4

**Marlborough 1, 2, 3**

**7:30am – 8:30am**

**Sharing Paperwork that Actually Works**

*Chair and Facilitator: Martin Hildebrandt (DE)*

### PLENARY SESSION 3 – T CELL IMMUNOTHERAPY

**New Zealand 1, 2**

**8:45am – 10:15am**

**Chairs:**

- Helen Heslop (US)

**Speakers:**

- Stan Riddell (US) – Design of chimeric receptors and composition of T cell products for adoptive therapy
- Carl June (US) – Engineered T cells for cancer therapy
- Malcolm Brenner (US) – Will Cellular Immunotherapies for Cancer Ever Become Standard of Care?

### QUALITY AND OPERATIONS TRACK 5

**Marlborough 1, 2, 3**

**8:45am – 10:15am**

**Cellular Therapy Product Testing**

*Chair: Annette Trickett (AU)*

**Speakers:**

- Pamela Clark (AU) – Optimised Microbial Screening for HPC
- Christopher Tsai (TW) – Stem Cell Testing: Meeting the needs of clinical applications
- Elaine Coustan-Smith (SG) – Flow Cytometry methods for product testing in NK cell therapy trials

### ORAL ABSTRACT PRESENTATIONS 4

**New Zealand 1, 2**

**10:45am – 12:15pm**

**Immunotherapy and Dendritic Cells**

*Chair: Stephan Mielke (DE)*

**Presenters:**

- Inge Jedema (NL) – Hematopoiesis-specific T-cells may contribute to GVHD reactivity by induction of collateral damage to non-hematopoietic tissues during an ongoing profound gvl reaction
- Chrystal Louis (US) – A phase II study of carboplatin and docetaxel followed by Epstein-Barr virus specific cytotoxic T lymphocytes for refractory/refractory EBV-positive nasopharyngeal carcinoma
- Hermann Bohnenkamp (DE) – Automated in vitro generation of tri-virus-specific CD4+ and CD8+ T-lymphocytes for adoptive immunotherapy
- Patrick Hanley (US) – Naive t-cell-derived CTL recognize atypical epitopes of CMVPP65 with higher avidity than CMV-seropositive donor-derived CTL – a basis for treatment of post-transplant viral infection by adoptive transfer of T-cells from virus-naive donors
- Chun Ma (AU) – Prophylactic infusion of multi-virus specific T cells for management of viral reactivation and infection in patients post allogeneic hematopoietic stem cell transplantation (HSCT)
- Minhtran Ngo (US) – An antigen presenting complex for the generation of broad-specificity effector T lymphocytes for the treatment of EBV-associated malignancies

### ORAL ABSTRACT PRESENTATIONS 5

**Epsom 1, 2, 3**

**10:45am – 12:15pm**

**Regenerative Medicine and Translational Process Development**

*Co-Chairs: Robert Deans (US) and Ohad Karnieli (IL)*

**Presenters:**

- Kong Then (UK) – Autologous cultivated oral mucosal epithelial cells transplantation (COMET) with amniotic membrane based sheets for severe ocular chemical injury
- Sue Ngein Leow (MY) – Subretinal transplantation with human umbilical cord-derived mesenchymal stem cells delays retinal degeneration in royal college of surgeons rats
- Jaroslav Michalek (CZ) – Stem cell therapy of osteoarthritis using stromal vascular fraction cells
- Audrey Varin (FR) – The CD200/CD200R axis: new control mechanism of bone remodeling
- Inge Jedema (NL) – Production of leukemia-reactive T-cells via a good manufacturing practice procedure for treatment of patients with acute or chronic B-cell malignancies after allogeneic stem cell transplantation

### STRATEGIES FOR COMMERCIALIZATION TRACK 6

**New Zealand 3, 4**

**10:45am – 12:15pm**

**Clinical Themes Across Commercialization: Cord Blood Expansion Products**

*Co-Chairs: Robert Nordon (AU) and Claudia Zylberberg (US)*

**Speakers:**

- Shelly Heimfeld (US) – Frozen, pre–expanded cord blood as an off-the-shelf universal blood stem cell source
- Ian McNiece (US) – The Role of Academia in Development of Cellular Therapy Products
- Lynnet Koh (US) – Improving Stem Cell Software: Targeting Selectins for Homing and Engraftment of Cells in Regenerative Medicine
### QUALITY AND OPERATIONS TRACK 6

**Roundtable Debate: Pros and Cons in the Cellular Therapy Field**

**CHAIR:** LYNN O’DONNELL (US)

**Time:** 10:45am – 12:15pm

**Location:** Marlborough 1, 2, 3

### LUNCH WITH EXHIBITS

**Time:** 12:15pm – 1:45pm

**Location:** Auckland Room

### ANNUAL GENERAL MEETING

**Time:** 12:30pm – 1:30pm

**Location:** New Zealand 1, 2

Corporate Tutorial **kSep Systems** (Refer to Corporate Guide for Details)

### PLENARY SESSION 4 – COMMERCIAL PROGRESS IN REGENERATIVE MEDICINE

**CHAIR:** DAWN DRISCOLL (US)

**Time:** 1:45pm – 3:15pm

**Location:** New Zealand 1, 2

**SPEAKERS:**
- Timothy Allsopp (US) – Commercial development of regenerative medicines: trials & tribulations
- Evan Snyder (US) – The rational use of cell–based therapies – viewpoint from a scientist who advises regulatory agencies
- Sharron Gargosky (US) – Orchestrating Autologous Dendritic Cell Therapy Clinical Trials Across 15 Countries

### QUALITY AND OPERATIONS TRACK 7

**Challenging Quality Situations**

**CHAIR:** LIZABETH CARDWELL (US)

**Time:** 1:45pm – 3:15pm

**Location:** Marlborough 1, 2

**PANELISTS:**
- Cheryl Hutchins (AU)
- Vicki Antonenas (AU)
- Dhana Gounder (NZ)
- Martin Bleasdale (AU)
- Massimo Dominici (IT)

### COFFEE BREAK WITH EXHIBITS

**Time:** 3:30pm – 3:45pm

**Location:** Auckland Room

### WORKSHOP 3

**Regenerative Medicine for Cardiac and Neurological Disease**

**CHAIR:** JANET MACPHERSON (AU)

**Time:** 3:30pm – 5:00pm

**Location:** Epsom 1, 2, 3

**SPEAKERS:**
- James Chong (AU) – Cardiac Regeneration Using Cell Therapy
- Chris Bredeson (CA) – Autologous Hematopoietic Stem Cell Transplantation as a Paradigm for Immune Repair and Reinduction of Immune Tolerance – A Clinician’s Perspective
- Bronwen Connor (NZ) – Regenerating the Brain

### WORKSHOP 4

**Immune Therapy for GVHD**

**CHAIR:** GEOFF HILL (AU)

**Time:** 3:30pm – 5:00pm

**Location:** New Zealand 1, 2

**SPEAKERS:**
- Geoff Hill (AU) – Cytokine modulation in transplantation: Mouse and man
- John Koreth (US) – Regulatory T cell homeostasis in GVHD – Role of Interleukin–2

### STRATEGIES FOR COMMERCIALIZATION TRACK 7

**Approval and Post-Approval Experience**

**CHAIR:** ANTONIO LEE (KR)

**Time:** 3:30pm – 5:00pm

**Location:** New Zealand 3, 4

**SPEAKERS:**
- Douglas Arm (US) – Autologous Cell Therapy at the Point–Of–Care: Building a Global Business
- Chul–Won Ha (KR) – CARTiSTEM(R) – World’s First Allogeneic Stem Cell Drug for OA: Clinical Results and Post–Approval Status Update
- Anish S. Majumdar (IN) – An open label, multicentric, dose–ranging Phase II clinical study for evaluating the safety and efficacy of pooled allogeneic bone marrow–derived mesenchymal stem cells for treating patients with critical limb ischemia due to Buerger’s disease

### QUALITY AND OPERATIONS TRACK 8

**Disaster Planning and Recovery**

**CHAIR:** SUSY KIRWAN (NZ)

**Time:** 3:30pm – 5:00pm

**Location:** Marlborough 1, 2, 3

**SPEAKERS:**
- Cheryl Hutchins (AU) – Disaster Planning in a Cellular Therapy Facility – Experiences from the 2011 Brisbane Flood
- Hemant Patel (NZ) – The Christchurch Experience
- John Miller (US) – Medical Response to Marrow Toxic Injury Events: The Radiation Injury Treatment Network (RITN)
Wednesday April 24, 2013 continued

5:00pm – 6:00pm
MASTER CLASS 3
How to Run a Large GMP Facility
CHAIR: ADRIAN GEE (US)
SPEAKERS:
Adrian Gee (US) – GMP Manufacturing in Texas – where Bigger is Expected to be Better
Bruce Levine (US) – Design and Operation of Two Cell Processing Sites Within the Hospital of the University of Pennsylvania, or “Centrifigration by Technology”
Dominic Wall (AU) – Good governance for good manufacturing– commercial and regulatory challenges

5:00pm – 6:30pm Poster Session 2
New Zealand Foyer

7:00pm – midnight
GALA – LOCATION: AUCKLAND WAR MEMORIAL MUSEUM

Thursday April 25, 2013

7:00am – 3:00pm
REGISTRATION
Auckland Promenade

7:30am – 8:30am
TECHNICAL SESSION 2
NK Cells
CHAIR: KATY REZVANI (US)
SPEAKERS:
Katy Rezvani (US) – Ex vivo expanded cord blood Natural Killer cells as a novel therapeutic for lymphoid malignancies
Dario Campana (SG) – NK cell therapy of cancer

7:30am – 8:30am
TECHNICAL SESSION 3
Novel Cell Expansion Technologies
CHAIR: RAEVYN BROADY (CA)
SPEAKERS:
David DiGiusto (US) – In vitro expansion and in vivo evaluation of adult hematopoietic stem and progenitor cells
Juan Vera (US) – Optimized Manufacture of CAR−T Cells for Clinical Applications
Megan Levings (CA) – Expanding and tracking human regulatory T cells

7:30am – 8:30am
STRATEGIES FOR COMMERCIALIZATION TRACK 8
Downstream Logistics of Commercial Cell Products
CHAIR: SHIRLEY BARTIDO (US)
SPEAKERS:
Kim Raineri (SG) – Packaging and Delivery of Cell Therapy Products by a CMO
Liz Cardwell (US) – Stability and Traceability of Cellular Therapy Products during Shipment
Morey Kraus (US) – Roadmap to Clinical Utility for Newborn Stem Cell Products

7:30am – 8:30am
QUALITY AND OPERATIONS TRACK 9
BEACON Cell Therapy Bioprocessing Tools and Reagents Database
CHAIR: LYNN O’DONNELL (US)
SPEAKERS:
Brian Poole (CA) – The Tools & Reagents Database – Past, Present and Future
Michelle Keir (AU) – A User’s Perspective

8:45am – 10:15am
PLENARY SESSION 5 – ISCT–ASBMT JOINT SESSION: VIRUS SPECIFIC T CELLS
CHAIR: DAVID GOTTlieb (AU)
SPEAKERS:
David Gottlieb (AU) – Rebuilding immunity to prevent infection after stem cell transplant
Ann Lean (US) – Extending the range and applicability of antigen specific T cells for viral infection
Richard O’Reilly (US) – The potential and limitations of HLA non–identical transplant donor and third party donor derived virus–specific T−cells in stem cell and organ transplantation

Coffee and tea will be available prior to the start of the first morning sessions.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:45am – 10:15am | QUALITY AND OPERATIONS TRACK 10  
Cryobiology, Cryopreservation and Post-Thaw Process  
CHAIR: PING LAW (SG)  
SPEAKERS:  
Jason Acker (CA) – Cryobiology 101: The response of cell–based therapeutics to cryopreservation  
Zbigniew M. Szczepiorkowski (US) – Cryopreservation – when the function really matters...  
Shelly Heimfeld (US) – Cell Therapy Cryopreservation: Issues and Challenges with Stability Assessment and Post-thaw Processing |
| 10:15am – 10:45am | COFFEE BREAK WITH EXHIBITS  
Auckland Room |
| 10:45am – 11:45am | ORAL ABSTRACT PRESENTATIONS 6  
Nervous System Repair/Cardiovascular Regeneration  
PRESENTERS:  
Matthias Klugmann (AU) – AAV-based gene therapy approaches for the treatment of canavan disease  
Hossein Bahavarand (IR) – Transplantation of anterior-specified neural progenitors derived from human induced pluripotent stem cell improves the repair of the crushed optic nerve  
Nasser Aghdami (IR) – Phase III randomized clinical trial comparing the effects of autologous bone marrow derived MNC and CD133 cells transplantation in ami patients during cabg  
Kelly Ledford (US) – Potential atheroprotective effects of ixmyelocel-T cellular therapy |
| 10:45am – 11:45am | ORAL ABSTRACT PRESENTATIONS 7  
Gene Therapy  
CHAIR: JOHN RASKO (AU)  
PRESENTERS:  
Bruce Levine (US) – Adoptive transfer of gene-modified T-cells engineered to express high-affinity TCR’s for cancer-testis antigens NY-ESO-1 or LAGE-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT)  
Saar Gill (US) – Effective targeting of primary human acute myeloid leukemia using ANTI-CD123 chimeric antigen receptor engineered T cells  
Amit Khot (AU) – Autologous peripheral blood T lymphocytes transduced with an anti Lewisy chimeric receptor gene can be infused safely and persist in patients with Lewisy positive acute myeloid leukaemia  
Gunnar Kvalheim (NO) – Clinical experiences with therapeutic DC vaccines targeting autologous cancer stem cells in glioblastoma |
| 10:45am – 11:45am | QUALITY AND OPERATIONS TRACK 11  
Worldwide Surveys on T–Cells and MSCs  
CHAIR: SHANNON EAKER (US)  
MODERATOR/PRESENTER: KNUT NISS (US)  
PANELISTS:  
Bruce Levine (US), David DiGiusto (US), Austin Wang (TW), Jennifer Ho (TW) |
| 10:45am – 12:15pm | REGULATIONS AROUND THE WORLD SESSION 1  
New Zealand 1, 2  
SPEAKERS:  
Glenn Smith (TGA, Australia) – Regulation of Cell Therapies in Australia  
Stewart Jessamine (MedSafe, New Zealand) – New Zealand’s regulatory framework for cells and tissues  
Lee Lee Ong (Health Sciences Authority, Singapore) – Regulation of human cell– and tissue–based therapeutic products  
Tetsuya Kusakabe (Pharmaceuticals and Medical Devices Agency, Japan) – Regulatory updates on Cellular and Tissue–based products in Japan |
| 11:45am – 1:15pm | LUNCH WITH EXHIBITS  
Auckland Room |
| 12:00pm – 1:00pm | Corporate Tutorial  
Elsevier (Cytotherapy)  
(Refer to Corporate Guide for Details)  
New Zealand 3, 4  
Corporate Tutorial  
Charter Medical  
(Refer to Corporate Guide for Details)  
Epsom 1, 2, 3 |
### Thursday April 25, 2013 continued

#### WORKSHOP 5
**GI Disorders**
**CHAIR:** SARAH YOUNG (NZ)
**SPEAKERS:**
- Hootie Warren **(US)** – Dissecting and exploiting the autologous immune response to colorectal cancer
- Sarah Young **(NZ)** – Identification and activation of CD4 T cells from patients with colorectal cancer and Crohn’s disease
- Marian Sturm **(AU)** – Allogeneic Mesenchymal Stromal Cell Treatment for Biologic Refractory Crohn’s Disease

#### WORKSHOP 6
**Cell Therapies for Solid Tumors**
**CHAIR:** RAJIV KHANNA (AU)
**SPEAKERS:**
- Michael Kershaw **(AU)** – Genetic redirection of T cells against the Lewis-Y tumor associated antigen
- Steve Grupp **(US)** – Adapting successful CAR therapy to solid tumors - can we move beyond CD19
- Rajiv Khanna **(AU)** – Cellular immunotherapy for infectious complications and human malignancies: A new paradigm in personalized medicine

#### QUALITY AND OPERATIONS TRACK 12
**Daily Technical Challenges Encountered by Cellular Therapy Laboratories:**
“When a good day turns bad... now what am I supposed to do?”
**CHAIR:** LIZETTE CABALLERO (US)
**Panelists:**
- Lizette Caballero **(US)**, Vicki Antonenas **(AU)**, Thomas Leemhuis **(US)**

#### REGULATIONS AROUND THE WORLD SESSION 2
**SPEAKERS:**
- Youngjoo Park **(Korea FDA)** – Korea Regulatory Framework on Cell Therapy Products
- Yi-Chu Lin **(Taiwan FDA)** – Regulatory Development of Cell Therapy Products in Taiwan
- Paula Salmikangas **(Finnish Medicines Agency)** – Development and authorization of cell–based therapies in Europe
- Liz Anne Gillham–Eisen **(Health Canada)** – The Regulation of Cellular Therapies in Canada

#### BEST POSTER AND ORAL ABSTRACT AWARDS PRESENTATION & EXHIBITOR PASSPORT WINNERS ANNOUNCEMENTS
(Refer to Corporate Guide)

#### PLENARY SESSION 6 – GENE THERAPY
**CHAIR:** PETER BROWETT (AU)
**SPEAKERS:**
- Steve Wilton **(AU)** – Therapeutic alternative splicing as a customized genetic therapy: hope and hype
- Gwendolyn Binder–Scholl **(US)** – TCR Engineered T Cell Therapy for Oncology
- Matt During **(US)** – Gene therapy, after years in the nursery is it finally of age?

#### QUALITY AND OPERATIONS TRACK 13
**Small GMP Facility Management**
**CHAIR:** PING LAW (SG)
**SPEAKERS:**
- Lynn O’Donnell **(US)** – 2013: A Space Odyssey – Quest for More or Making the Most of What You Have
- Ping Law **(SG)** – Who is the Manager of a Small Facility: an Expert in Technology, Business or Regulatory Affairs?